Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg, Illkirch, France.
Proteins. 2012 Nov;80(11):2552-61. doi: 10.1002/prot.24136. Epub 2012 Jul 28.
The relationship between the structures of protein-ligand complexes existing in the crystal and in solution, essential in the case of fragment-based screening by X-ray crystallography (FBS-X), has been often an object of controversy. To address this question, simultaneous co-crystallization and soaking of two inhibitors with different ratios, Fidarestat (FID; K(d) = 6.5 nM) and IDD594 (594; K(d) = 61 nM), which bind to h-aldose reductase (AR), have been performed. The subatomic resolution of the crystal structures allows the differentiation of both inhibitors, even when the structures are almost superposed. We have determined the occupation ratio in solution by mass spectrometry (MS) Occ(FID)/Occ(594) = 2.7 and by X-ray crystallography Occ(FID)/Occ(594) = 0.6. The occupancies in the crystal and in solution differ 4.6 times, implying that ligand binding potency is influenced by crystal contacts. A structural analysis shows that the Loop A (residues 122-130), which is exposed to the solvent, is flexible in solution, and is involved in packing contacts within the crystal. Furthermore, inhibitor 594 contacts the base of Loop A, stabilizing it, while inhibitor FID does not. This is shown by the difference in B-factors of the Loop A between the AR-594 and AR-FID complexes. A stable loop diminishes the entropic energy barrier to binding, favoring 594 versus FID. Therefore, the effect of the crystal environment should be taken into consideration in the X-ray diffraction analysis of ligand binding to proteins. This conclusion highlights the need for additional methodologies in the case of FBS-X to validate this powerful screening technique, which is widely used.
蛋白质-配体复合物在晶体和溶液中的结构之间的关系,在基于 X 射线晶体学的片段筛选(FBS-X)中至关重要,这一直是争议的焦点。为了解决这个问题,同时对两种抑制剂(Fidarestat(FID;K(d) = 6.5 nM)和 IDD594(594;K(d) = 61 nM))进行共结晶和浸泡,它们与 h-醛还原酶(AR)结合。晶体结构的亚原子分辨率允许区分两种抑制剂,即使结构几乎完全重叠。我们通过质谱(MS)Occ(FID)/Occ(594) = 2.7 和 X 射线晶体学 Occ(FID)/Occ(594) = 0.6 确定了溶液中的占有率。晶体和溶液中的占有率相差 4.6 倍,这意味着配体结合能力受到晶体接触的影响。结构分析表明,暴露于溶剂中的 Loop A(残基 122-130)在溶液中具有柔性,并参与晶体内部的包装接触。此外,抑制剂 594 与 Loop A 的底部接触,稳定了它,而抑制剂 FID 则没有。这可以通过 AR-594 和 AR-FID 复合物中 Loop A 的 B 因子之间的差异看出。稳定的环降低了结合的熵能障碍,有利于 594 而不是 FID。因此,在蛋白质配体结合的 X 射线衍射分析中,应该考虑晶体环境的影响。这一结论突出了在 FBS-X 的情况下需要额外的方法学来验证这种广泛使用的强大筛选技术。